Table 7.

GRADE Summary of Findings reporting the comparative efficacy of different pharmacological agents for MAINTAINING CLINICAL REMISSION in all patients with moderate to severe Crohn’s disease, who have responded to induction therapy, regardless of prior biologic exposure, based on network meta-analysis

Medications	Relative effect (Odds ratio, 95% CI)	Overall Quality of Evidence
Selected agents vs. Infliximab
Adalimumab	1.54 (0.75–3.17)	Low (very serious imprecision)
Certolizumab pegol	0.78 (0.41–1.51)	Low (very serious imprecision)
Vedolizumab	0.81 (0.39–1.67)	Very low (very serious imprecision, intransitivity*)
Ustekinumab	0.71 (0.37–1.36)	Very low (very serious imprecision, intransitivity*)
Selected agents vs. Adalimumab
Certolizumab pegol	0.51 (0.27–0.96)	Moderate (imprecision)
Vedolizumab	0.51 (0.26–1.07)	Low (imprecision, intransitivity*)
Ustekinumab	0.46 (0.24–0.87)	Low (imprecision, intransitivity*)
Selected agents vs. Certolizumab pegol
Vedolizumab	1.03 (0.54–1.97)	Very low (very serious imprecision, intransitivity*)0
Ustekinumab	0.90 (0.51–1.59)	Very low (very serious imprecision, intransitivity*)
Selected agents vs. Vedolizumab
Ustekinumab	0.87 (0.46–1.66)	Low (very serious imprecision)

^*All comparisons of vedolizumab and ustekinumab vs. TNFα antagonists were rated down for intransitivity, since a significant proportion of patients in trials of vedolizumab and ustekinumab had previously been exposed to TNFα antagonists